Cogent Biosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGCogent Biosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings contraction of 15% provides fundamental context to the price action. Investors should exercise caution due to high volatility (53% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $33.95 | +12.21% | ABOVE |
| 50 SMA | $34.61 | +10.09% | ABOVE |
| 100 SMA | $35.65 | +6.87% | ABOVE |
| 150 SMA | $36.48 | +4.45% | ABOVE |
| 200 SMA | $31.69 | +20.22% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is COGT in an uptrend right now?
COGT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is COGT overbought or oversold?
COGT's RSI (14) is 70. The stock is in neutral territory, neither overbought nor oversold.
Is COGT outperforming the market?
COGT has a Relative Strength (RS) Rating of 83 out of 99. Yes, COGT is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is COGT in its 52-week range?
COGT is trading at $38.10, which is 87% of its 52-week high ($43.73) and 85% above its 52-week low ($7.07).
How volatile is COGT?
COGT has a Beta of 1.26 and 52-week volatility of 53%. It's more volatile than the S&P 500 - expect bigger swings.